Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Novel ctDNA technology for liver cancer detection by immunoprecipitation of tumor associated ctDNA fragments and analysis by qPCR

Wednesday, March 6, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses a novel ctDNA technology aimed at improving liver cancer detection through the immunoprecipitation of tumor-associated ctDNA fragments, followed by analysis using qPCR. This research was presented at the EASL Liver Cancer Summit 2024, highlighting its potential significance in cancer diagnostics. The technology may offer enhanced accuracy in identifying liver cancer markers.
Price reaction · baseline $17.4 (2024-03-05 close) · hit pre-market · 2 other VNRX headline(s) in the window, move may be shared
day 0 close
+14.3%
day 1
+13.8%
day 3 · peak
+21.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Introduction of novel ctDNA technology for liver cancer detection.
  • Utilizes immunoprecipitation for enhanced accuracy.
  • Presented at a reputable summit, indicating peer recognition.

Full Press Release Details

Poster titled: Novel ctDNA technology for liver cancer detection by immunoprecipitation of tumor associated ctDNA fragments and analysis by qPCR
Presented at: EASL Liver Cancer Summit 2024
Pamart et al

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What is the focus of the presented ctDNA technology?

The technology focuses on liver cancer detection using immunoprecipitation of tumor-associated ctDNA fragments.

Where was the ctDNA technology presented?

It was presented at the EASL Liver Cancer Summit 2024.

What method is used for analyzing ctDNA fragments?

The ctDNA fragments are analyzed using qPCR.

Who are the authors of the research?

The research was conducted by Pamart et al.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare ctDNA liver cancer EASL Summit diagnostics qPCR
Last updated: Mar 6, 2024

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk